Photo from LUNGevity Foundation/X
Jun 1, 2024, 11:46
Phase 2 study OptiTROP-Lung01 had promising results in patients with advanced NSCLC – LUNGevity Foundation
LUNGevity Foundation shared on X/Twitter:
“Phase 2 study (OptiTROP-Lung01) had promising results in patients with advanced NSCLC . Phase 3 study versus immunotherapy is underway. More ADC studies are needed.”
Source: LUNGevity Foundation/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 28, 2024, 18:51
Sep 28, 2024, 18:42
Sep 28, 2024, 18:18
Sep 28, 2024, 17:52
Sep 28, 2024, 17:41
Sep 28, 2024, 16:29